A detailed history of Charles Schwab Investment Management Inc transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 346,498 shares of GLUE stock, worth $2.44 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
346,498
Previous 311,800 11.13%
Holding current value
$2.44 Million
Previous $1.17 Million 57.46%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$3.59 - $6.97 $124,565 - $241,845
34,698 Added 11.13%
346,498 $1.84 Million
Q2 2024

Aug 12, 2024

BUY
$3.38 - $7.86 $206,916 - $481,173
61,218 Added 24.43%
311,800 $1.17 Million
Q1 2024

May 08, 2024

BUY
$4.26 - $8.46 $21,385 - $42,469
5,020 Added 2.04%
250,582 $1.77 Million
Q4 2023

Feb 06, 2024

BUY
$2.5 - $5.93 $7,672 - $18,199
3,069 Added 1.27%
245,562 $1.39 Million
Q3 2023

Nov 08, 2023

BUY
$4.78 - $7.22 $58,674 - $88,625
12,275 Added 5.33%
242,493 $1.16 Million
Q2 2023

Aug 09, 2023

BUY
$4.53 - $8.4 $26,418 - $48,988
5,832 Added 2.6%
230,218 $1.58 Million
Q1 2023

May 11, 2023

SELL
$5.95 - $8.21 $583 - $804
-98 Reduced 0.04%
224,386 $1.75 Million
Q4 2022

Feb 13, 2023

BUY
$6.71 - $9.72 $75,614 - $109,534
11,269 Added 5.29%
224,484 $1.71 Million
Q3 2022

Nov 14, 2022

BUY
$7.17 - $12.16 $695,353 - $1.18 Million
96,981 Added 83.44%
213,215 $1.74 Million
Q2 2022

Aug 15, 2022

SELL
$6.15 - $14.99 $56,370 - $137,398
-9,166 Reduced 7.31%
116,234 $1.12 Million
Q1 2022

May 13, 2022

BUY
$10.36 - $20.41 $417,901 - $823,298
40,338 Added 47.42%
125,400 $1.76 Million
Q4 2021

Feb 11, 2022

BUY
$16.28 - $27.15 $82,832 - $138,139
5,088 Added 6.36%
85,062 $1.74 Million
Q3 2021

Nov 16, 2021

BUY
$18.59 - $42.21 $1.49 Million - $3.38 Million
79,974 New
79,974 $1.78 Million

Others Institutions Holding GLUE

About Monte Rosa Therapeutics, Inc.


  • Ticker GLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,713,900
  • Market Cap $329M
  • Description
  • Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...
More about GLUE
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.